AIRLINK 69.92 Increased By ▲ 4.72 (7.24%)
BOP 5.46 Decreased By ▼ -0.11 (-1.97%)
CNERGY 4.50 Decreased By ▼ -0.06 (-1.32%)
DFML 25.71 Increased By ▲ 1.19 (4.85%)
DGKC 69.85 Decreased By ▼ -0.11 (-0.16%)
FCCL 20.02 Decreased By ▼ -0.28 (-1.38%)
FFBL 30.69 Increased By ▲ 1.58 (5.43%)
FFL 9.75 Decreased By ▼ -0.08 (-0.81%)
GGL 10.12 Increased By ▲ 0.11 (1.1%)
HBL 114.90 Increased By ▲ 0.65 (0.57%)
HUBC 132.10 Increased By ▲ 3.00 (2.32%)
HUMNL 6.73 Increased By ▲ 0.02 (0.3%)
KEL 4.44 No Change ▼ 0.00 (0%)
KOSM 4.93 Increased By ▲ 0.04 (0.82%)
MLCF 36.45 Decreased By ▼ -0.55 (-1.49%)
OGDC 133.90 Increased By ▲ 1.60 (1.21%)
PAEL 22.50 Decreased By ▼ -0.04 (-0.18%)
PIAA 25.39 Decreased By ▼ -0.50 (-1.93%)
PIBTL 6.61 Increased By ▲ 0.01 (0.15%)
PPL 113.20 Increased By ▲ 0.35 (0.31%)
PRL 30.12 Increased By ▲ 0.71 (2.41%)
PTC 14.70 Decreased By ▼ -0.54 (-3.54%)
SEARL 57.55 Increased By ▲ 0.52 (0.91%)
SNGP 66.60 Increased By ▲ 0.15 (0.23%)
SSGC 10.99 Increased By ▲ 0.01 (0.09%)
TELE 8.77 Decreased By ▼ -0.03 (-0.34%)
TPLP 11.51 Decreased By ▼ -0.19 (-1.62%)
TRG 68.61 Decreased By ▼ -0.01 (-0.01%)
UNITY 23.47 Increased By ▲ 0.07 (0.3%)
WTL 1.34 Decreased By ▼ -0.04 (-2.9%)
BR100 7,394 Increased By 99.2 (1.36%)
BR30 24,121 Increased By 266.7 (1.12%)
KSE100 70,910 Increased By 619.8 (0.88%)
KSE30 23,377 Increased By 205.6 (0.89%)

imageKARACHI: A single member bench of Sindh High Court, comprising Justice Mohammad Shafi Siddiqui, through an order on Thursday overthrew the decision by the provincial health authorities to purchase costly hepatitis drug from two multinational companies (MNCs).

The bench acknowledging that this was depriving local pharma companies of level playing ground scraped tender to buy costly hepatitis medicine from MNCs.

Justice Mohammad Shafi Siddiqui who had reserved the judgement on March 6, announcing the same Thursday, termed the process of purchase of medicine illegal, unlawful and without legal grounds; scrapping the tender issued for purchase of medicine worth Rs 250 million.

The detailed judgement came on a petition filed by various local pharmaceutical firms against the rejection of their products used for the treatment of Hepatitis B and C.

Earlier, the court had rejected the plea by the health department for partial purchase of hepatitis medicine from multinationals on the grounds that the court was hearing the case on priority basis therefore limited purchase could not be allowed.

The health authorities had pleaded to relax the stay order on the purchase of injection so that 25 per cent of medicine costing around Rs. 60.2 million could be bought for 33,000 patients, of whom some 1,800 were at terminal stage.

Advocates Faisal Siddiqui, Shahid Memon and Abdus Sattar Pirzada, the counsel for the petitioners, told the court that the government was playing games with mala fide intentions to benefit certain influential, causing great losses to public exchequer and interest of poor hepatitis patients.

They questioned as to why many leading health institutions including Government of Balochistan and Government of AJK had been purchasing and using the locally produced medicines for decades with no complaints, if they were harmful to human health.

The counsel further argued that the government had issued licenses to the local national pharmaceutical firms to produce the drug, allowing it to sell the medicine in local market as well as to export it.

They said one of the drug rejected on quality grounds was the largest selling pharma item in the country and it was produced by Getz Pharma that was the only one in Pakistan having WHO recognition for its laboratory.

The counsel said that the government officials continued to misguide government, masses and the court for their ulterior motives to buy costly medicine from two major multinationals.

Copyright APP (Associated Press of Pakistan), 2015

Comments

Comments are closed.